Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination

We report on the onset of minimal change disease (MCD) presenting with anasarca after a second dose of the messenger RNA (mRNA)-based Pfizer-BioNTech vaccine against coronavirus disease 2019 (COVID-19). A 75-year-old previously healthy male was admitted with rapidly progressive anasarca and proteinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Seiji, Fugo, Kazunori, Yamazaki, Kazuto, Terawaki, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Exceptional Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499758/
https://www.ncbi.nlm.nih.gov/pubmed/34938534
http://dx.doi.org/10.1093/ckj/sfab156
_version_ 1784580363806310400
author Kobayashi, Seiji
Fugo, Kazunori
Yamazaki, Kazuto
Terawaki, Hiroyuki
author_facet Kobayashi, Seiji
Fugo, Kazunori
Yamazaki, Kazuto
Terawaki, Hiroyuki
author_sort Kobayashi, Seiji
collection PubMed
description We report on the onset of minimal change disease (MCD) presenting with anasarca after a second dose of the messenger RNA (mRNA)-based Pfizer-BioNTech vaccine against coronavirus disease 2019 (COVID-19). A 75-year-old previously healthy male was admitted with rapidly progressive anasarca and proteinuria of 7.7 g/day following the second dose. A kidney biopsy revealed MCD with nephrotic syndrome. He was treated with intravenous methylprednisolone followed by prednisolone, leading to complete remission after 35 days in the hospital. Since definite causality between the vaccine and MCD remains unclear, awareness of this potential adverse effect of mRNA vaccines is important to determine its true incidence and frequency.
format Online
Article
Text
id pubmed-8499758
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-84997582021-10-08 Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination Kobayashi, Seiji Fugo, Kazunori Yamazaki, Kazuto Terawaki, Hiroyuki Clin Kidney J Exceptional Case We report on the onset of minimal change disease (MCD) presenting with anasarca after a second dose of the messenger RNA (mRNA)-based Pfizer-BioNTech vaccine against coronavirus disease 2019 (COVID-19). A 75-year-old previously healthy male was admitted with rapidly progressive anasarca and proteinuria of 7.7 g/day following the second dose. A kidney biopsy revealed MCD with nephrotic syndrome. He was treated with intravenous methylprednisolone followed by prednisolone, leading to complete remission after 35 days in the hospital. Since definite causality between the vaccine and MCD remains unclear, awareness of this potential adverse effect of mRNA vaccines is important to determine its true incidence and frequency. Oxford University Press 2021-08-26 /pmc/articles/PMC8499758/ /pubmed/34938534 http://dx.doi.org/10.1093/ckj/sfab156 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Exceptional Case
Kobayashi, Seiji
Fugo, Kazunori
Yamazaki, Kazuto
Terawaki, Hiroyuki
Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination
title Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination
title_full Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination
title_fullStr Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination
title_full_unstemmed Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination
title_short Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination
title_sort minimal change disease soon after pfizer-biontech covid-19 vaccination
topic Exceptional Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499758/
https://www.ncbi.nlm.nih.gov/pubmed/34938534
http://dx.doi.org/10.1093/ckj/sfab156
work_keys_str_mv AT kobayashiseiji minimalchangediseasesoonafterpfizerbiontechcovid19vaccination
AT fugokazunori minimalchangediseasesoonafterpfizerbiontechcovid19vaccination
AT yamazakikazuto minimalchangediseasesoonafterpfizerbiontechcovid19vaccination
AT terawakihiroyuki minimalchangediseasesoonafterpfizerbiontechcovid19vaccination

Ejemplares similares